The Relationship Between the Residual Renal Function and Osteoporosis Treatment

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02304887

Enrollment

1000

Registered

2014-12-02

Start date

2006-01-31

Completion date

2019-01-31

Last updated

2016-11-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoporosis

Keywords

Osteoporosis, Bone mineral densisty, Renal function, CKD-MBD

Brief summary

The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.

Detailed description

Chronic kidney disease (CKD)- mineral and bone disorder (CKD-MBD) is one of the topic in osteoporosis treatment. As many osteoporotic patients are older, many patients are under the deterioration of the renal function. In addition, several drugs might have the potential for kidney damage. But the relationship between osteoporosis drugs and kidney damage is unclear. The main objective of this study is to reveal relationship between osteoporosis drugs and kidney damage.

Interventions

DRUGBis, SERM Teriparatide, Denosumab

Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

45 Years to No maximum

Healthy volunteers

Inclusion criteria

* Osteoporosis patients

Exclusion criteria

* eGFR \< 15

Design outcomes

Primary

Measure	Time frame
Longitudinal renal function changes by osteoporotic treatment	Up to 120 months

Countries

Japan

Contacts

Primary ContactRui Niimi, MD

furikakefuri@hotmail.co.jp(81)-59-365-0023

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026